GTCR-Backed Resonetics Acquires Distal Solutions

GTCR, a leading private equity firm, announced today that Resonetics has completed an acquisition of Distal Solutions.

Distal Solutions (“Distal”), based in Westborough, Massachusetts, specializes in the design and development of catheter-based delivery systems for interventional medical devices and implants.

Distal’s founder David Rezac, a 15-year veteran of the contract design and development industry, will lead Resonetics’ design and development efforts as well as further expansion in the California market. Distal Solutions represents the sixth add-on acquisition since GTCR invested in Resonetics in February 2018.

The acquisition furthers the company’s strategy to build a market leader in precision micro-manufacturing and design of complex interventional medical devices and componentry. With the addition of Distal’s design and development capabilities, Resonetics aims to further accelerate product development cycles and help customers advance their innovative product concepts to market more quickly.

GTCR made its initial investment in Resonetics in partnership with medical device industry executive Robert “Chip” Hance. GTCR initially partnered with Mr. Hance to form Regatta Medical in April 2017 to pursue opportunities in the medical device sector, and the investment in Resonetics represented another example of how GTCR executes The Leaders StrategyTM. Since GTCR’s investment, Mr. Hance has partnered with the Resonetics team, including CEO Tom Burns, to significantly grow the company’s revenue and EBITDA through organic growth and strategic add-on acquisitions.

Chip Hance, Executive Chairman of Resonetics, commented, “Consistent with our initial investment thesis for Resonetics, the acquisition of Distal Solutions strategically enhances Resonetics’ capabilities, and further establishes the company’s position as a leading service provider to interventional medical device companies.”

Sean Cunningham, Managing Director at GTCR, added, “We have great respect for what David and the Distal team has built, and we look forward to our partnership with them. This represents Resonetics’ sixth acquisition since our initial investment, and we expect to continue to aggressively pursue tuck-in acquisitions as well as more transformative opportunities.”

Kirkland & Ellis LLP provided legal counsel and PricewaterhouseCoopers served as accounting advisor to GTCR.

SourceGTCR
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy